Selank vs Semax: side-by-side comparison.

Research on Selank vs Semax has characterized two distinct functional profiles: Selank as an anxiolytic, Semax as a nootropic/neuroprotective agent. Same lab, same length, two mechanistically different molecules.

One Moscow lab — the Institute of Molecular Genetics — developed both peptides in the 1990s. The research goal was to produce short, stable peptide compounds from neuroactive natural sequences.

Both share the same scaffold. Both share the same stability design. The active core of each peptide derived from a different natural starting point, which accounts for their distinct mechanisms and approved indications.

How do the structures compare?

Both peptides share the same architecture. Active 4-amino-acid core, plus a Pro-Gly-Pro tail. The core engages receptors in the central nervous system. The tail confers enzyme resistance, keeping the molecule intact long enough to reach its targets. Both also carry an N-acetyl cap at the N-terminus, which further protects against proteolytic degradation.

The cores are where they diverge:

• Selank's core: Thr-Lys-Pro-Arg. This sequence is tuftsin — a natural human tetrapeptide produced in the spleen by proteolytic cleavage of IgG. Discovered at Tufts University in the 1970s, tuftsin has been studied primarily for its immunomodulatory signaling activity.
• Semax's core: Met-Glu-His-Phe. This is a fragment of ACTH(4-7). Research has established that this fragment retains brain-active properties distinct from ACTH's cortisol-releasing activity, engaging neuronal targets independently of the HPA axis.

The differing origins account for their distinct pharmacological profiles. Selank carries tuftsin-derived immunomodulatory activity; Semax carries ACTH-derived neuroactive properties. Same structural shell, different active cores.

How do the mechanisms compare?

Studies have characterized Selank as acting primarily through calming (GABAergic/serotonergic) and immune-modulatory pathways. Semax research has focused on neurotrophic and neuroprotective pathways. Some overlap has been reported (both have shown GABA-related activity; both modulate stress cytokines), but the primary mechanistic profiles are distinct.

Selank's mechanism. A 2022 rat study by Konstantinopolsky reported that Selank reduced anxiety-like behavior in rodent models at a level comparable to diazepam. A 2021 study reported reductions in stress-driven inflammatory cytokines (IL-1β, IL-6, TNF-α) in preclinical stress models. Together, these findings form the preclinical basis for Selank's anxiolytic and immunomodulatory classification.

Semax's mechanism. A 2024 Filippenkov study reported that Semax restored near-normal expression of ~1,171 genes in rat brain tissue 24 hours after experimental stroke. Italian researchers reported that Semax binds copper and inhibits copper-driven amyloid-beta aggregation in membrane models. A 2025 spinal-cord-injury study identified opioid-receptor binding activity. Across these studies, Semax has been characterized as a multi-pathway neuroprotective compound.

Both stories are coherent. Semax has more papers behind it. Not because Selank is poorly characterized — because the same lab put more effort into Semax over the last five years.

Regulatory status: Russia yes, the West no

Both have Russian regulatory approval — placing them ahead of most compounds commonly marketed as "research peptides." Neither is approved by the FDA or EMA.

• Selank. Approved in Russia since 2009. Intranasal (nasal-drop) formulation. Approved indication: generalized anxiety disorder. Russian clinical protocols used short-course administration (days to weeks).
• Semax. Approved in Russia for ischemic stroke (acute treatment and recovery phase) and cognitive disorders (post-stroke cognitive deficit, acquired brain injury). Intranasal formulation. Applied in acute stroke care and the post-stroke recovery window per Russian clinical protocols.

Outside Russia, both are available as research-grade reference compounds. The most commonly studied off-label application in preclinical and observational contexts is cognitive function in healthy subjects — also the application with the thinnest controlled evidence for either compound.

Dose ranges reported in the literature

Russian clinical studies have employed intranasal nasal-drop administration for both peptides. Published preclinical studies have reported dose ranges spanning 0.3 mg/kg (single-dose anxiolytic models, Konstantinopolsky) to 5–450 µg/kg across Semax stroke and chronic-stress protocols. These figures appear in the cited literature and are noted here as reference data for researchers reviewing the preclinical record.

The Panikratova 2020 fMRI study administered both peptides intranasally to healthy adult research subjects using standard Russian nasal drops. Measurable brain-imaging changes were observed within 20 minutes of administration — the most relevant Western proxy for assessing pharmacodynamic onset in humans.

Selank

Tuftsin analog 7 aa N-acetylated

The same Russian-school anxiolytic peptide cited across the comparative literature in this article. Lab-verified identity and purity.

View Selank

Administration routes in the literature: intranasal vs parenteral

Russian clinical validation for both peptides used the intranasal (nasal-drop) route. Pharmacologically, intranasal delivery bypasses first-pass hepatic metabolism and enables partial direct olfactory/trigeminal transport to the CNS — a pathway supported by the Pro-Gly-Pro stability tail, which preserves both peptides against proteolytic degradation long enough to traverse the mucosal surface.

A distinct pharmacokinetic profile has been reported for parenteral administration. Subcutaneous delivery produces different peak plasma concentrations, eliminates the direct nose-to-brain transport component, and alters the absorption half-life. Studies comparing intranasal and parenteral routes directly for these two peptides have not been published in the Western literature as of the time of writing.

The Panikratova fMRI study and Russian clinical approvals both rely exclusively on intranasal administration. Parenteral dosing regimens reported in grey-market research contexts have not been validated by controlled trial evidence in either Russian or Western programs.

Selank vs Semax: the side-by-side reference

For quick reference, here is the comparison in one place.

Indication mapping: how Russian approvals distinguish them

The Russian regulatory record provides the clearest framework for distinguishing how each compound has been studied and approved.

• Anxiety models — Selank. Russian clinical trials and approvals target generalized anxiety disorder. The Konstantinopolsky (2022) rat model reported diazepam-comparable anti-anxiety effects without sedation — the preclinical basis for the anxiolytic classification.
• Stroke and cognitive deficit models — Semax. Russian approval covers acute ischemic stroke and post-stroke cognitive deficit. The Filippenkov (2024) transcriptomics study reported restoration of ~1,171 disrupted genes in rat brain 24 hours post-stroke, supporting the neuroprotective classification.
• Cognitive enhancement in healthy subjects. Neither peptide has been validated by controlled trial for enhancement in neurologically intact subjects. Semax is more frequently studied in this context, but Russian approval is restricted to deficit models.

The two peptides are not interchangeable. Different parent molecules, different mechanisms, different approved indications constitute distinct research profiles requiring separate evaluation.

Co-administration: what the literature covers

The Panikratova 2020 fMRI study examined Selank and Semax as separate arms (vs placebo) — not as a combined administration. No published Western study has examined the two peptides in combination.

Russian clinical programs do not document routine co-administration protocols for these two compounds. Combination regimens reported in observational or grey-market contexts represent extrapolations from the single-compound literature rather than controlled co-administration evidence.

Pharmacologically, the two peptides engage distinct receptor systems, and no direct pharmacokinetic or mechanistic interaction has been reported in the published literature. The absence of a reported interaction is not equivalent to a characterized safety profile for co-administration.

Semax

11 mg ≥99% pure Lyophilized

ACTH(4-10) analog · 7 aa, N-acetylated. The same reference compound used across the comparative literature. COA available with each lot.

Learn more

Safety: similar profile, one difference

Russian clinical trials have reported both peptides as well-tolerated at intranasal doses used in the approved short-course indications. The most commonly reported adverse event in those trials was mild nasal irritation. No major drug interactions, dependence liability, or sedation have been documented in the Russian clinical record at approved doses.

The same limitations apply to both compounds. Russian regulatory approval is confined to short-course use (days to weeks). Long-term safety data for extended off-label use have not been published. Theoretical pharmacodynamic interactions have been identified (GABAergic agents for both; opioid receptor activity for Semax; serotonergic and other neuroactive agents for both), but none have been characterized in controlled clinical studies.

One distinction in the emerging literature: a 2025 spinal-cord-injury study identified Semax opioid-receptor binding activity. This mechanistic finding has not been evaluated in the context of co-administration with opioid medications in a clinical study. No analogous opioid-receptor signal has been reported for Selank.